会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 35. 发明授权
    • Antihypertensive tricyclic azepine derivatives useful as inhibitors of
enkephalinase and ACE
    • 抗高血压三环吖庚因衍生物可用作脑啡肽酶和ACE的抑制剂
    • US5644055A
    • 1997-07-01
    • US569117
    • 1995-12-20
    • Stephane De Lombaert
    • Stephane De Lombaert
    • A61K31/55A61K38/00A61P9/00A61P13/02A61P15/00A61P25/24A61P25/26C07D471/04C07D471/06C07D487/06C07K5/078A61K31/47C07D487/04
    • C07D471/06C07D487/06C07K5/06139A61K38/00
    • Disclosed are the compounds of formula I ##STR1## wherein X represents oxo, one hydroxy or lower alkoxy and one hydrogen, or two hydrogens;R.sub.a and R.sub.b independently represent hydrogen, hydroxy, lower alkoxy, nitro, amino or halogen; or R.sub.a and R.sub.b on adjacent carbons taken together represent lower alkylenedioxy;R.sub.c represents hydrogen, lower alkyl or aryl-lower alkyl;R represents hydrogen or acyl;R.sub.1 represents hydrogen, lower alkyl, aryl, aryl-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, biaryl, biaryl-lower alkyl or trifluoromethyl;R.sub.2 represents hydrogen or lower alkyl; or R.sub.1 and R.sub.2 together with the carbon to which they are attached represent cycloalkylene or benzo-fused cycloalkylene;m represents one or two;n represents zero or one;COOR.sub.3 represents carboxyl or carboxyl derivatized in form of a pharmaceutically acceptable ester; disulfide derivatives formed from said compounds wherein R is hydrogen;and pharmaceutically acceptable salts thereof;pharmaceutical compositions comprising said compounds; methods for preparation of said compounds; intermediates; and methods of treating disorders in mammals which are responsive to ACE and NEP inhibition by administration of said compounds to mammals in need of such treatment.
    • PCT No.PCT / EP94 / 01978 Sec。 371 1995年12月20日第 102(e)1995年12月20日,PCT PCT 1994年6月17日PCT公布。 公开号WO95 / 01353 日期1995年1月12日公开是式I的化合物或低级烷氧基和一个氢或两个氢; R a和R b独立地表示氢,羟基,低级烷氧基,硝基,氨基或卤素; 或相邻碳原子上的Ra和Rb代表低级亚烷基二氧基; Rc表示氢,低级烷基或芳基 - 低级烷基; R代表氢或酰基; R 1表示氢,低级烷基,芳基,芳基 - 低级烷基,环烷基,环烷基 - 低级烷基,联芳基,联芳基 - 低级烷基或三氟甲基; R2代表氢或低级烷基; 或R 1和R 2与它们所连接的碳一起代表亚环烷基或苯并稠合的亚环烷基; m表示一个或两个; n表示0或1; COOR3表示以药学上可接受的酯的形式衍生的羧基或羧基; 由所述化合物形成的二硫化物衍生物,其中R是氢; 及其药学上可接受的盐; 包含所述化合物的药物组合物; 所述化合物的制备方法; 中间体 以及通过向需要这种治疗的哺乳动物施用所述化合物来治疗对ACE和NEP抑制有反应的哺乳动物疾病的方法。
    • 36. 发明授权
    • Phosphono substituted tetrazole derivatives
    • 膦酰取代的四唑衍生物
    • US5273990A
    • 1993-12-28
    • US940118
    • 1992-09-03
    • Stephane De Lombaert
    • Stephane De Lombaert
    • C07F9/6524C07D257/04A01N57/24
    • C07F9/6524
    • The present invention relates to the N-phosphonomethyl substituted tetrazole derivatives of formula I ##STR1## and tautomers thereof wherein R.sub.1 is aryl or biaryl; n is zero, 1 or 2 pharmaceutically acceptable mono- or di-ester derivatives thereof in which one or both of the acidic hydroxy groups of the phosphono functional group are esterified in form of a pharmaceutically acceptable mono- or di-ester; and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; methods for preparation of said compounds and for the preparation of intermediates; and methods of treating disorders in mammals which are responsive to the inhibition of neutral endopeptidases by administration of said compounds to mammals in need of such treatment.
    • 本发明涉及式I的N-膦酰基甲基取代的四唑衍生物(Ⅰ)及其互变异构体,其中R 1是芳基或联芳基; n是0,1或2个药学上可接受的单酯或二酯衍生物,其中膦酰基官能团的酸性羟基中的一个或两个以药学上可接受的单酯或二酯的形式酯化; 及其药学上可接受的盐; 包含所述化合物的药物组合物; 制备所述化合物和制备中间体的方法; 以及通过向需要这种治疗的哺乳动物施用所述化合物来治疗哺乳动物疾病的方法,所述疾病对中性内肽酶的抑制有反应。